United States Cushing’s Disease Treatment Market and Forecast 2020-2026

                                          
Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal with injury or infection. Increasing levels of cortisol increases the blood sugar and can even cause diabetes mellitus. However the disease is also caused due to excess production of hypothalamus corticotropin releasing hormone (CRH) which stimulates the synthesis of cortisol by the adrenal glands.

Cushing’s disease treatment market revenue is growing with a stable growth rate, this is attributed to increasing number of pipeline drugs. Also increasing the interest of pharmaceutical companies to develop Cushing disease drugs is a major factor contributing to the revenue growth of the Cushing disease treatment market over the forecast period. Current and emerging players’ focuses on physician education and awareness regarding availability of different drugs for curing Cushing disease, thus increasing the referral speeds, time to diagnosis and volume of diagnosed Cushing disease individuals. Growing healthcare expenditure and increasing awareness regarding Cushing syndrome aids in the revenue growth of Cushing’s disease treatment market.

The increasing number of new product launches also drives the market for Cushing’s disease Treatment devices. However availability of alternative therapies for curing Cushing syndrome is expected to hamper the growth of the Cushing’s disease treatment market over the forecast period.

Market Analysis and Insights: Global Cushing’s Disease Treatment Market


The United States Cushing’s Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

In Jan 2020, Recordati Rare Diseases received marketing authorization valid throughout the European Union for Isturisa which is a medicine used to treat adults with Cushing’s syndrome, a disease characterised by an excess production of the hormone cortisol by the adrenal glands, two glands situated above the kidneys.

Isturisa contains the active substance osilodrostat. The active substance in Isturisa, osilodrostat, blocks the activity of an enzyme involved in the production of cortisol called 11-beta-hydroxylase. This reduces cortisol production and cortisol levels in the body, thereby relieving the symptoms of the disease.
Isturisa is effective at reducing elevated cortisol levels in patients with Cushing’s syndrome. Side effects are considered manageable by adjusting the dose or temporarily stopping treatment.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cushing’s Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cushing’s Disease Treatment market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure

lasting success in the global Cushing’s Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cushing’s Disease Treatment market.

Cushing’s Disease Treatment Breakdown Data by Type

 	
Ketoconazole
 	
Mitotane
 	
Aminoglutethimide
 	
Metyrapone
 	
Mifepristone
 	
Etomidate
 	
Pasireotide

Cushing’s Disease Treatment Breakdown Data by Application

 	
Hospital Pharmacies
 	
Retail Pharmacies
 	
Drug Stores
 	
Clinics
 	
E-Commerce/Online Pharmacies

In the competitive analysis section of the report, leading as well as prominent players of the global Cushing’s Disease Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

 	
CORCEPT THERAPEUTICS
 	
HRA Pharma
 	
Strongbridge Biopharma
 	
Novartis